• Mario Cazzola, Ermanno Puxeddu, Josuel Ora, and Paola Rogliani.
• Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy. mario.cazzola@uniroma2.it.
• Mol Diagn Ther. 2019 Oct 1; 23 (5): 603-614.

AbstractIn recent years, there has been a great deal of interest in the identification and validation of blood-based biomarkers for clinical use in chronic obstructive pulmonary disease (COPD). We now have panels of blood biomarkers that potentially hold great promise as they show statistically significant associations with COPD, but biomarkers for the diagnosis of COPD remain elusive. In fact, they are yet to demonstrate sufficient accuracy to be accepted in clinical use, and many are not specific to COPD but more related to inflammation (e.g. interleukin-6) or associated with other chronic diseases such as diabetes (e.g. soluble receptor for advanced glycation endproducts [sRAGE]). Although no single blood-based biomarker has demonstrated clinical utility for either the diagnosis or progression of COPD, it has been suggested that combinations of individual markers may provide important diagnostic or prognostic information; however, the interpretation of COPD biomarker results still requires thought and many questions remain unanswered.

17 keywords...

hide…